First Nasally-Administered Pharmaceutical Treatment for Dry Eye Disease Approved by US FDA with Aptar's Nasal Pump SystemBusiness Wire • 10/25/21
Aptar Announces the Completion of the Acquisition of a Majority Stake in VoluntisBusiness Wire • 09/02/21
AptarGroup, Inc. (ATR) CEO Stephan Tanda on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/01/21
Aptar Enters into Agreement with Weihai Hengyu Medical Products to Add Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug DeliveryBusiness Wire • 07/28/21
Why the Earnings Surprise Streak Could Continue for AptarGroup (ATR)Zacks Investment Research • 07/27/21
Aptar Announces the Signature of a Share Purchase Agreement Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 Per ShareBusiness Wire • 07/23/21
Aptar Announces Strategic Collaboration with YAT, a Chinese Online Skincare Company, to Develop Range of Products and Services for the Skincare MarketBusiness Wire • 07/07/21
AptarGroup (ATR) Eyeing Voluntis to Expand in Digital TherapeuticsZacks Investment Research • 06/23/21
Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital TherapeuticsBusiness Wire • 06/22/21